EGFR and neoplasm: Tumours assigned to this subtype had higher mutation scores in multiple epidermal growth factor receptor (EGFR) family pathways, in cell–cell contact and cellular structure (“adherens junction”, “gap junction”), the immune system (“cytokine–cytokine receptor interaction”) and in brain tissue-associated pathways (including “gonadotropin-releasing hormone signalling”).